uPAR產(chǎn)品信息
英文名稱:Urokinase plasminogen activator surface receptor
中文名稱:尿激酶型纖溶酶原激活物表面受體
靶點(diǎn)別稱:uPAR,PLAUR,CD87,MO3
物種:Human / Mouse
標(biāo)簽:His Tag & Avi Tag / His Tag / Fc Tag
屬性:Protein / Cell / Beads
標(biāo)記:Biotin-labeled / FITC Labeled / Unconjugated / PE Labeled / APC Labeled
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
uPAR分子背景
尿激酶纖溶酶原激活物表面受體(U-PAR)也稱為PLAUR、單核細(xì)胞激活抗原Mo3、CD抗原CD87。PLAUR包含三個(gè)UPAR/Ly6結(jié)構(gòu)域。U-PAR在大腦外側(cè)區(qū)的神經(jīng)元中表達(dá)(在蛋白質(zhì)水平上),也在大腦中表達(dá)。PLAUR/CD87與MRC2、SRPX2和SORL1相互作用。PLAUR/UPAR作為尿激酶型纖溶酶原激活物的受體,在定位和促進(jìn)纖溶酶形成方面發(fā)揮作用。U-PAR介導(dǎo)U-PA的蛋白水解非依賴性信號(hào)轉(zhuǎn)導(dǎo)激活效應(yīng)。
uPAR用戶評(píng)價(jià)
關(guān)鍵字: uPAR;uPAR蛋白;PLAUR;CD87;CD87蛋白;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。